226545-65-9

Basic information

• Product Name: N^α-tert-butoxycarbonyl-L-isoleucyl-L-prolyl-glycyl-L-leucyl-L-prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine benzyl ester
• Synonyms: N^α-tert-butoxycarbonyl-L-isoleucyl-L-prolyl-glycyl-L-leucyl-L-prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine benzyl ester
• CAS NO: 226545-65-9
• Molecular Weight: 1089.38
• Mol File: 226545-65-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N^α-tert-butoxycarbonyl-L-isoleucyl-L-prolyl-glycyl-L-leucyl-L-prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N^α-tert-butoxycarbonyl-L-isoleucyl-L-prolyl-glycyl-L-leucyl-L-prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine benzyl ester(226545-65-9)
• EPA Substance Registry System: N^α-tert-butoxycarbonyl-L-isoleucyl-L-prolyl-glycyl-L-leucyl-L-prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine benzyl ester(226545-65-9)

Safety Data

• Hazardous Substances Data: 226545-65-9(Hazardous Substances Data)

Upstream product

• 13139-16-7 N-(tert-butyloxycarbonyl)-L-isoleucine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 23680-31-1 BOC-O-benzyl-L-serine 
• 99092-17-8 N-tert-butoxycarbonyl-O-benzyl-L-seryl-L-leucine benzyl ester 
• 171518-47-1 N-tert-butoxycarbonyl-L-leucyl-O-benzyl-L-seryl-L-leucine benzyl ester 
• 226545-57-9 N-tert-butoxycarbonyl-L-prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine benzyl ester 
• 226545-59-1 N-tert-butoxycarbonyl-L-leucyl-L-prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine benzyl ester 
• 226545-61-5 N-tert-butoxycarbonylglycyl-L-leucyl-L-prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine benzyl ester 
• 226545-63-7 N^α-tert-butoxycarbonyl-L-prolyl-glycyl-L-leucyl-L-prolyl-L-leucyl-O-benzyl-L-seryl-L-leucine benzyl ester 

Relevant articles and documents

Synthesis of cancer peptide antigen-lipid A analog conjugates for synthetic vaccines

Conjugates 6 and 7 of cancer peptide antigen with N-tetradecanoyl L- serine-β-alanine-containing D-glucosamine derivative structurally related to lipid A as an immunoadjuvant were synthesized for the development of totally synthetic vaccines against cancers. The mitogenic activities of compounds 6 and 7 were stronger than that of lipid A analog 3.